| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8441888 | European Journal of Cancer | 2015 | 9 Pages |
Abstract
Substantial LVSI, in contrast to focal or no LVSI, was the strongest independent prognostic factor for pelvic regional recurrence, distant metastasis and overall survival. Therapeutic decisions should be based on the presence of substantial, not 'any' LVSI. Adjuvant EBRT and/or chemotherapy should be considered for stage I EC with substantial LVSI.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Tjalling Bosse, Elke E.M. Peters, Carien L. Creutzberg, Ina M. Jürgenliemk-Schulz, Jan J. Jobsen, Jan Willem M. Mens, Ludy C.H.W. Lutgens, Elzbieta M. van der Steen-Banasik, Vincent T.H.B.M. Smit, Remi A. Nout,